EMA (EU)
GUIDANCE FINAL
Draft guideline on the clinical requirements for medicines intended for the treatment of sickle cell disease
Published: 9/24/2026Detected: 9/24/2026
Summary preview
Sets out EMA CHMP/HAEMWP clinical development expectations for medicines targeting sickle cell disease, including how to design confirmatory efficacy studies, select patients, and define efficacy and safety endpoints.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accounthematology
pediatrics
clinical
safety
labeling
manufacturing
#sickle cell disease
#vaso-occlusive crises
#haemolysis
#clinical requirements
#confirmatory studies
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026